And of course without getting our hopes up too much we must be getting close to announcing the end of PH2 meeting with the FDA for Pitt-Hopkins Syndrome,
This should be due in February 2025 roughly. That the begs the question if NEU got breakthrough for Phelan-McDermid Syndrome where does that leave Pity-Hopkins.
It’s hard to imagine one indication being approved for use and the second group waiting for 2-3 years for their treatment.
One things for sure if we get Breakthrough Designation the auction will really start hotting up. Because a Breakthrough Designation will draw a lot of attention to NEU.
Ann: Update - Notification of buy-back - NEU, page-87
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$16.48 |
Change
-0.290(1.73%) |
Mkt cap ! $2.076B | |||
| Open | High | Low | Value | Volume |
| $16.58 | $16.74 | $16.40 | $9.107M | 549.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 864 | $16.43 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $16.50 | 1668 | 1 |
View Market Depth
| Last trade - 16.10pm 25/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |